A Randomized, Controlled Laboratory Classroom Study of Serdexmethylphenidate and d-Methylphenidate Capsules in
Scott H Kollins1,2, Rene Braeckman3, Sven Guenther3
1Duke ADHD Program, Durham, North Carolina, USA.
Journal of Child and Adolescent Psychopharmacology
|October 29, 2021
Summary
Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) capsules effectively improved attention-deficit/hyperactivity disorder (ADHD) symptoms in children aged 6-12 compared to placebo. This ADHD treatment demonstrated a rapid onset and extended duration of action with a favorable safety profile.
Area of Science:
- Pharmacology
- Neuroscience
- Pediatric Psychiatry
Background:
- Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder in children.
- Stimulant medications are a cornerstone of ADHD treatment, but optimal dosing and duration of effect remain critical considerations.
- Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) is a novel, once-daily oral formulation designed for extended symptom control.
Purpose of the Study:
- To assess the efficacy and safety of once-daily SDX/d-MPH compared to placebo in pediatric patients diagnosed with ADHD.
- To determine the onset and duration of therapeutic effect in a controlled laboratory classroom setting.
- To evaluate the safety and tolerability profile of SDX/d-MPH in children aged 6-12 years.
Main Methods:
- A randomized, double-blind, placebo-controlled, dose-optimized laboratory classroom study was conducted in children (6-12 years) with ADHD.
- Participants underwent a 3-week open-label dose optimization phase followed by a 7-day double-blind treatment phase comparing optimal SDX/d-MPH dose to placebo.
- Efficacy was measured using the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale and the Permanent Product Measure of Performance (PERMP). Safety was monitored via adverse events, vital signs, and electrocardiograms.
Main Results:
- SDX/d-MPH demonstrated statistically significant improvements in mean postdose SKAMP-Combined scores compared to placebo (p < 0.001).
- Significant treatment effects were observed from 1 to 10 hours postdose, with a potential onset as early as 0.5 hours and duration up to 13 hours.
- Both PERMP-Attempted and PERMP-Correct scores showed significant improvement with SDX/d-MPH versus placebo (p < 0.001).
- No serious adverse events were reported; common adverse events included insomnia and decreased appetite, consistent with stimulant treatments.
Conclusions:
- Once-daily SDX/d-MPH is an effective treatment for ADHD symptoms in children aged 6-12, showing rapid onset and sustained efficacy.
- The medication was found to be safe and well-tolerated, with an adverse event profile comparable to other stimulant therapies.
- SDX/d-MPH offers a promising therapeutic option for managing pediatric ADHD, addressing the need for extended symptom control.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.9K
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
10.5K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
426
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
426
01:28Adrenergic Agonists: Mixed-Action Agents
1.1K
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
1.1K
02:01Group Design
9.8K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
9.8K
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
398
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
398
01:16Experimental Designs
16.0K
An experimental design is a systematic process that allows researchers to evaluate the relationship between dependent and independent variables. There are three widely used types of experimental design - pre-experimental design, true experimental design, and quasi-experimental design. In pre-experimental design, the researcher compares the data before and after some interventions or treatments. The true-experimental design has more than one purposefully created group, a commonly measured...
16.0K
02:07Blind Procedures
12.4K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
12.4K